Notícias

RapAdmin

High-Dose Flu Vaccine Raises Protection in Over-75s From 40 to 72 Percent, in Men and Women Alike

Johns Hopkins researchers followed 82 young adults and 84 adults over 75 through the 2019 to 2020 flu vaccine season. Young women had higher antibody levels against the H3N2 strain than young men, and more flu-recognising B cells. That gap was absent in the older group. In lab dishes, adding estradiol to blood cells from young women increased antibody output, and blocking the estrogen receptor, NF-kB or TNF removed the effect. The mechanistic work rests on four donors per group. The female advantage was already present before vaccination, and the size of the response to the vaccine did not differ significantly between the sexes.

Women generally produce more antibodies than men after vaccination, and that gap narrows in old age. A team at Johns Hopkins set out to explain why, and their answer centres on estrogen acting directly on the cells that make antibodies.

The study ran two groups in parallel. Eighty-two healthcare workers aged 18 to 49 received the standard flu shot. Eighty-four community-dwelling adults over 75 received the high-dose version recommended for their age. Blood was drawn before vaccination, then at 7 and 28 days.

Among the young adults, women had higher neutralising antibody levels against the H3N2 strain at both the start and the end. They also carried more B cells able to recognise the flu protein hemagglutinin. None of this held for H1N1, where almost everyone already had strong immunity. And none of it held in the over-75s, where men and women looked alike.

The team measured twelve steroid hormones by mass spectrometry. Young women had far higher estradiol and estrone than anyone else. In the older group the pattern flipped slightly, with men having more estrogen than women.

Gene activity in sorted B cells pointed the same way. A week after vaccination, B cells from young women showed higher activity in estrogen-response genes and in an inflammatory signalling route known as TNF signalling via NF-kB. Many of the genes involved carry DNA sequences that the estrogen receptor can bind.

The most direct evidence came from cell culture. When blood cells from young women were exposed to flu protein plus estradiol overnight, more cells secreted antibody and each secreted more of it. Tamoxifen, which blocks the estrogen receptor in B cells, cancelled the boost. So did drugs that block NF-kB or TNF. Cells from men did not respond to estradiol at all. Cells from older women still responded, though less strongly.

There are reasons for caution. The young women’s advantage existed before the needle went in. Measured as fold increase or as the share of people who seroconverted, the response to the vaccine was statistically the same in men and women. In fact, a slightly larger share of young men than young women seroconverted. The culture experiments used four donors per group and frozen cells. Two-thirds of the young women were on birth control of mixed types, which alters natural hormone levels. The two age groups received different vaccine doses, and nobody between 50 and 74 was enrolled, so the menopause transition is missing from the picture.

The authors raise the idea of estrogen as a vaccine adjuvant for postmenopausal women. This study did not test that. It shows that estrogen receptor signalling can increase antibody secretion from young women’s B cells in a dish, and that older women’s cells retain some of that capacity.

Actionable Insights

This study does not support changing anything about how or whether you get a flu shot.

What it shows in practical terms:

  • Before vaccination, 63 percent of young women already had protective H3N2 antibody levels, against 28 percent of young men. That is a 35 percentage point gap, or about 2.3 times as likely.
  • After vaccination the gap nearly closed: 94 percent of women and 87 percent of men were protected. Young men benefited at least as much from the shot.
  • In adults over 75 receiving the high-dose vaccine, 72 percent reached protective levels but only about 35 percent seroconverted, with no sex difference. Vaccination still raised protection from 40 to 72 percent in that group.
  • In culture, estradiol raised the number of antibody-secreting cells from young women by roughly half and nearly doubled antibody output per cell. These are approximate readings from four donors.

For postmenopausal women on hormone therapy, the finding that older B cells still respond to estrogen is of interest, but no clinical benefit was measured. For people on TNF-blocking drugs, the culture result is a hypothesis only.

Overall, young women have higher H3N2 antibody levels and more flu-specific B cells than young men. Estradiol can increase antibody secretion from young women’s blood cells in culture via the estrogen receptor. This mechanism explains sex and age differences in vaccine response in people. Estrogen may improve vaccine protection if given to older women

The practical message is that young men and older adults of both sexes have the most to gain from the vaccine.

Context and Source

Leitura Relacionada:

RapAdmin

Edinburgh researchers tested how well 23 different “biological age” measures, all taken at age 73, predicted who died over the next 16 years in 861 Scottish adults born in 1936. Plasma protein clocks that estimate the age of 11 organs did predict mortality, with liver, immune and heart clocks performing best. They were matched or edged out by the GrimAge2 epigenetic clock, brain volume on MRI, lung function and a cognitive test score. Telomere length predicted nothing. A screen of 9,703 blood proteins flagged GDF15 as the single strongest protein signal.

Blood tests that claim to tell you the age of your liver, heart or brain are now sold directly to consumers. They rest on a 2023 Stanford method that reads thousands of plasma proteins and assigns each organ an age. What nobody had done is line those organ clocks up against older, cheaper measures of aging in the same people and see which best predicts death.

The Lothian Birth Cohort 1936 is well suited to that test. Its members were all born in the same year, so chronological age is effectively removed as a confounder. At about age 73 they gave blood, had brain scans, blew into a spirometer, squeezed a dynamometer, walked six metres against a stopwatch and sat 13 cognitive tests. Sixteen years later, 444 of the 861 had died.

Every organ clock was linked to mortality. A person whose organ looked one standard deviation “older” than their peers’ had a 16 to 43 percent higher risk of dying at any point in follow-up. Liver, immune system and heart led the list.

They were not the best performers. GrimAge2, an epigenetic clock built from DNA methylation and trained directly on death records, carried a 62 percent higher risk per standard deviation. Smaller total brain volume, weaker lung function and lower cognitive scores each came in at 44 to 52 percent. Telomere length, long marketed as a biological age test, showed no association at all.

When the team put 21 markers into one model, only four kept an independent signal: total brain volume, white matter damage on MRI, general cognitive ability and walking time. Those four explained about 19 percent of the variation in mortality risk. Adding the other 17 raised that to 23 percent.

The second half of the paper screened 9,703 individual proteins. GDF15, an stress-response protein, topped the list at 56 percent higher risk per standard deviation, followed by WFDC2 and TIMP1. Proteins linked to higher risk clustered around immune and inflammatory signalling. Proteins linked to lower risk clustered around chromatin and DNA maintenance, a pattern the authors read as genomic stability

Several cautions apply. The organ clocks were trained to predict age in a different cohort on an older version of the assay, while GrimAge2 was trained to predict death, so the contest is not level. The gaps between top markers were not formally tested and their confidence intervals overlap. The joint model used only 460 people. The cohort is healthy, white and Scottish, and everything was measured once.

What the study does show is that simple functional measures hold their own against an 11,000-protein assay. A spirometer and a stopwatch remain competitive with the newest molecular tools for predicting survival in the eighth decade of life.

Actionable Insights

What this study offers is guidance on which measurements carry information at around age 73.

Low-cost measures did as well as costly ones. Lung function (FEV1) and a cognitive score each predicted death about as strongly as the best proteomic organ clock. Walking speed stayed informative after accounting for everything else. The cohort average was 4.4 seconds to cover six metres, about 1.4 metres per second.

To put the numbers in plain terms: half the cohort died in 16 years. By my rough calculation, a person one standard deviation “older” on GrimAge2 had about a 69 percent chance of dying in that time, against about 36 percent for someone one standard deviation “younger”. For the liver clock the equivalent figures are about 65 and 40 percent. For telomere length there was no difference.

Practical takeaways:

  • Telomere length testing had no predictive value here.
  • Organ age tests carry real signal, but no more than spirometry or an epigenetic clock.
  • GDF15 was the strongest single blood protein. It is a research marker with no agreed action threshold.
  • Smoking history, lung function and brain health are the modifiable areas this data points toward.

Context and Source

  • Open Access Paper: Multimodal Ageing Biomarkers and Plasma Proteomic Signatures Associated With All-Cause Mortality
  • Institution: The University of Edinburgh (Lothian Birth Cohorts; Institute of Genetics and Cancer), with co-authors at the University of Exeter, the US National Institute on Aging and the University of Texas at Austin
  • Country: United Kingdom (Scotland)
  • Journal: Aging Cell (Wiley, for the Anatomical Society), Accepted 23 September 2026.
  • Impact evaluation: The impact score of this journal is 7.7 (Journal Impact Factor, 2025 JCR data year), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal. It is a leading title within the aging-biology specialty.

Leitura Relacionada:

RapAdmin

This Science review argues that sex differences in aging and disease are not only hormonal. The X and Y chromosomes themselves act inside cells, independent of ovaries or testes. In women, a supposedly silent second X leaks gene activity, reawakens further with age, and creates a mixed population of cells running on either the mother’s or father’s X. In men, blood cells progressively lose the Y chromosome, which is linked to heart fibrosis, cancer, Alzheimer’s disease and earlier death. The authors propose these features as biomarkers and drug targets.

Women outlive men almost everywhere, including through famines and epidemics. The usual explanation is hormones. This review, from four US research groups, makes the case that a large part of the answer sits in the chromosomes themselves.

The evidence starts with an engineered mouse. In the “four core genotypes” model, the gene that triggers testis development is moved off the Y chromosome, so researchers can breed XX animals with testes and XY animals with ovaries. This separates chromosomes from hormones. In these mice, having two X chromosomes extends survival whichever gonads the animal has.

Why would a second X help? Textbooks say one X in every female cell is switched off. That turns out to be only partly true. In humans, roughly 15 to 30 percent of genes on the “inactive” X stay switched on, giving female cells a higher dose of those genes. One of them, KDM6A, controls how DNA is packaged. Higher KDM6A activity is tied to cognitive resilience in Alzheimer’s disease in people, and boosting it rescued memory in mouse models, including in males.

The silent X also wakes up with age. In old female mice, a myelin gene called Plp1 reactivates on the inactive X in the brain, and raising Plp1 improved cognition in aged mice of both sexes. A third mechanism is mosaicism. Female tissue is a patchwork of cells using either the maternal or paternal X, while male cells have only the maternal copy. In mice, skewing the patchwork toward the maternal X accelerated brain aging.

The second X has costs. The same extra gene dose appears to drive autoimmunity, which is far more common in women. In mice, two X chromosomes also worsen injury after a heart attack or stroke and promote weight gain and fatty liver on a high-fat diet.

For men, the story is loss. With age, a growing fraction of white blood cells drop the Y chromosome entirely. This is the most common acquired chromosome change in aging men, and it tracks with cardiovascular disease, cancers, severe infections and Alzheimer’s disease. Mouse experiments suggest it is not just a bystander: giving mice Y-deficient blood cells caused heart scarring and shortened their lives. Smoking is the strongest known driver, and its effect is partly reversible. In tumors, Y loss predicts worse outcomes but a better response to checkpoint immunotherapy.

The authors want sex chromosome measurements built into diagnostics and clinical trials, and they see drug targets that could help both sexes. That is a proposal, not a result. The paper is a narrative review with no new data, the strongest causal evidence is in mice, and the human findings are mostly correlations. Y loss is even more common in centenarians, so it remains unsettled whether it harms, marks aging, or does both.

Actionable Insights

Very little here is actionable today, and the paper does not claim otherwise.

The one modifiable factor is smoking. It is the strongest known driver of Y chromosome loss in men’s blood and is linked to X loss in women. The review gives no numbers, but the primary study it cites reported, as I recall it, that current smokers had roughly 2.4 to 4.3 times the odds of Y loss, and that former smokers looked similar to never-smokers. Quitting appears to undo much of the excess.

To gauge why Y loss matters: in the UK Biobank study cited, men missing the Y in more than 40 percent of white cells had about a 31 percent higher risk of death from circulatory disease. If a man’s ten-year risk were 5 percent, that would mean about 6.5 percent. This is a modest association, not proof of cause.

There is no validated consumer test for Y loss, X-skew or X reactivation, and no threshold that would change your care. There is also no supplement or drug shown to raise KDM6A or PLP1 safely in humans.

Context and Source

  • Open Access Paper: X and Y chromosomes as determinants of aging and disease, 1 Oct 2026.
  • Institutions: University of California, San Francisco (Weill Institute for Neurosciences and Bakar Aging Research Institute); Spaulding Rehabilitation Hospital and Harvard Medical School; Oklahoma Medical Research Foundation and Oklahoma City VA Medical Center; University of Arizona Comprehensive Cancer Center
  • Country: USA
  • Journal: Science (AAAS)
  • Impact evaluation: The impact score of this journal is 45.8 (Journal Impact Factor, 2025 listing), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

RapAdmin

This narrative review argues that aging of the microvasculature (capillaries, their endothelial lining and supporting pericytes) is an active driver of organ decline, not a side effect of it. It describes a shared endothelial aging program that plays out differently in the brain, heart, kidney, lung, muscle, bone marrow and tumors. It separates rare senescent cells from a broader, population-wide drift in endothelial function, which has direct consequences for senolytic strategies. It then surveys candidate interventions, from exercise and metabolic drugs to VEGF signaling and endothelial reprogramming.

For more than three centuries, doctors have quoted Thomas Sydenham’s remark that a man is as old as his arteries. Two of Germany’s most prominent vascular biologists now argue that the saying points at the wrong vessels. In a review in Nature Cardiovascular Research, Stefanie Dimmeler and Hellmut Augustin make the case that the body’s smallest vessels, and the endothelial cells that line them, help set the pace of aging in every organ.

The central idea is that blood vessels are not plumbing. Endothelial cells send chemical instructions, called angiocrine signals, to the tissue around them. When those cells age, the instructions change. The review describes a shared aging program found in vessels throughout the body: less nitric oxide, more oxidative stress, DNA damage, a thinner sugar coating on the vessel lining, and stiffer surrounding tissue. The outcome depends on the organ. In the brain it appears as a leaky blood-brain barrier, in the heart as stiffening and heart failure with preserved ejection fraction, in the kidney as protein leaking into urine, and in muscle and bone as frailty and osteoporosis.

The most useful correction concerns senescent cells, the “zombie” cells that senolytic drugs are meant to remove. Single-cell studies show that truly senescent endothelial cells remain a small minority even in very old mice. Most of the endothelium instead drifts gradually into a less capable, mildly inflamed state. Killing a rare cell population cannot fix a problem that affects nearly every cell. It may also backfire: removing senescent endothelial cells worsened liver injury and pulmonary hypertension in mouse experiments.

Timing is another theme. Human protein data suggest blood vessels are among the first tissues to show aging, with an inflection near age 50. The authors argue that treatments helpful in midlife may be useless or harmful later. Statins illustrate the point. They partly mimic the vascular effects of exercise, yet their benefit shrinks in people over 75 without existing vascular disease, possibly because aged endothelial cells respond less to the drug’s signals.

On treatments, the review is candid about how little is proven. Exercise remains the best-supported way to improve endothelial function. Metformin, SGLT2 inhibitors and GLP-1 receptor agonists improve vascular measures, but nobody has shown whether they act on the vessel wall directly or simply improve whole-body metabolism. More exotic ideas, including boosting VEGF signaling, a mitochondrial drug called SUL-238 and reprogramming of endothelial cells, rest almost entirely on mouse work.

The authors end with a question they cannot answer: does rejuvenating vessels reverse organ aging, or only slow further decline? Readers should keep the paper’s nature in mind. It is a narrative review. Its value lies in the framework, and that framework is still a hypothesis.

Actionable Insights

The review contains no new trial data, so the numbers below come from the studies it cites.

  • Exercise is the only intervention the authors call established for vascular aging. The review gives no effect size for it.
  • Statins lower major vascular events by about 21 percent for each 1 mmol/L (39 mg/dL) drop in LDL cholesterol. If 20 of 100 people like you would have an event over ten years, that means about 16 instead, or 4 fewer. Over age 75 the reduction falls to about 13 percent, and in people over 75 without vascular disease it was not statistically distinguishable from zero.
  • SGLT2 inhibitors cut worsening heart failure or cardiovascular death from about 21 to 16 per 100 patients over 18 months in one landmark trial. That is 5 fewer per 100, in people who already had heart failure.
  • Senolytics are not ready. Fisetin did not extend lifespan in the most rigorous mouse testing program, and senescent cell removal caused harm in some models.
  • Vascular aging appears to accelerate around age 50, so blood pressure, lipids, urine albumin and fitness deserve attention in midlife rather than later.

Context/Source

  • Paywalled Paper: Vascular aging as a driver of organ dysfunction and systemic aging, Published 23 September 2026
  • Institutions: Institute of Cardiovascular Regeneration, Goethe University Frankfurt; German Center for Cardiovascular Research (DZHK); Cardio-Pulmonary Institute, Frankfurt; European Center for Angioscience, Heidelberg University, Mannheim; German Cancer Research Center, Heidelberg
  • Country: Germany
  • Journal: Nature Cardiovascular Research
  • Impact evaluation: The impact score of this journal is 12.6 (2025 Journal Impact Factor; 5-year 13.5), evaluated against a typical high-end range of 0 to 40 for top cardiovascular journals (0 to 60+ for top general science), therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

A 21-week, double-blind, placebo-controlled trial at Amsterdam UMC gave 31 people with fibrotic fatty liver disease (MASH, stage F2 to F3) intermittent dasatinib plus quercetin (D+Q) or placebo. On paired liver biopsies, 47% of the D+Q group improved by at least one fibrosis stage without worsening of MASH, against 7% on placebo. MASH resolved in 53% versus 7%. Single-nucleus RNA sequencing showed lower senescence and fibrosis gene signatures after treatment. Blood tests and liver stiffness scans did not move, side effects were about twice as common on D+Q, and the authors themselves call the result hypothesis-generating.

For a decade, senolytics have been long on mouse data and short on human proof. The idea is simple: aged, damaged cells that refuse to die pile up in tissues and secrete inflammatory and scar-promoting signals, so clearing them should relieve the tissue. Until now, no randomized human trial had shown that a senolytic changes the structure of a diseased organ under the microscope. This one does, in the liver, with large caveats.

Researchers recruited 31 adults with biopsy-confirmed MASH and moderate to advanced scarring. Seventeen received dasatinib, a leukemia drug, at 100 mg per day with 1,000 mg of quercetin, a plant flavonoid sold as a supplement. Fourteen received matching placebo. Dosing was sparse: three consecutive days a week for three weeks, then four weeks off, repeated three times. That is 27 dosing days across five months.

Three pathologists, blinded to both treatment and timepoint, scored biopsies taken before and after. Eight of 17 treated participants improved by at least one fibrosis stage without their steatohepatitis worsening. One of 14 placebo participants did. Nine of 17 on D+Q had resolution of MASH, against one on placebo. This happened without weight loss, which is the usual route to liver improvement in this disease.

The molecular data point the same way. Sequencing of individual liver cell nuclei showed that gene programmes associated with senescence and with collagen production fell after D+Q and did not fall after placebo. The proportion of hepatic stellate cells, the liver’s scar-producing cells, also dropped.

The reasons for caution are substantial. The whole primary result is eight responders against one. The relative risk of 6.59 carries a confidence interval running from 0.93 to 46.53, which technically includes no effect at all. In a worst-case analysis of the four missing biopsies, statistical significance disappears. Change one placebo patient from non-responder to responder and the headline finding is no longer significant.

The groups were also uneven at the start. The D+Q arm had twice the rate of type 2 diabetes and more people at the higher fibrosis stage, which leaves more room to improve.

None of the non-invasive measures agreed with the biopsies. Liver enzymes, stiffness scans, FIB-4, ELF and ProC3 showed no significant difference. Insulin resistance and continuous glucose data did not improve either, despite strong mouse evidence that they should.

Safety was acceptable but not clean. Adverse events hit 82% of the D+Q group versus 43% on placebo, mostly headache and gut complaints. Platelet counts fell by an adjusted 50 units relative to placebo. There were no cases of bone marrow suppression or heart rhythm changes.

The trial earns senolytics a larger liver study. It does not establish D+Q as a treatment, and 21 weeks says nothing about durability, cancer risk or long-term dasatinib exposure.

Actionable Insights

This trial does not justify self-treating with dasatinib, and that is the main take-home message.

The size of the claimed benefit: fibrosis improved in 47% of treated people versus 7% on placebo, an absolute gain of 40 percentage points. Put plainly, for every 2.5 people treated, one extra person improved. MASH resolution showed a 46-point gain. Those are very large effects, bigger than those reported for approved MASH drugs, which is itself a reason for suspicion. Small trials routinely overestimate, and the plausible range here runs from an 8-point to a 64-point gain.

The size of the cost: for every 2.5 people treated, one extra person had side effects.

Practical points:

  1. The benefit was shown only in people with biopsy-proven fibrotic MASH. It says nothing about healthy people taking D+Q for prevention.
  2. Quercetin alone was not tested. Nothing here supports quercetin supplements for liver health.
  3. Dasatinib is a prescription chemotherapy drug that lowers platelets, and it interacts with acid reducers and many common medications.
  4. Blood tests and liver scans did not detect the improvement. Anyone experimenting could not monitor whether it was working without a biopsy.
  5. If you have fatty liver disease, the proven options remain weight loss and approved drugs.

Context and Source

Leitura Relacionada:

RapAdmin

Researchers at Harvard-affiliated Spaulding Rehabilitation report that tiny blood-borne particles called extracellular vesicles (EVs), collected from ten sedentary older adults after 12 weeks of moderate aerobic exercise, pushed aged human cartilage cells toward a more youthful state in the dish. The same vesicles reduced cartilage damage scores when injected into the knees of old mice. The team traces the effect to microRNA-29, which appears to lift an epigenetic brake on the gene for alpha-Klotho.

Exercise is the first-line treatment for knee osteoarthritis, yet nobody has explained how a brisk walk reaches cartilage, a tissue with no blood supply. A paper in Nature Aging proposes an answer: the message travels in extracellular vesicles, nanoscale membrane bubbles that cells release into the bloodstream carrying short regulatory RNAs.

The team started at the computer. They reanalyzed a public dataset of ten older men sampled before and after a single cycling session and flagged 16 vesicle microRNAs that changed. Mapping the targets of those microRNAs onto a cartilage-specific gene network pointed to cell-matrix adhesion, the machinery by which cartilage cells sense the stiffness of their surroundings. One family, microRNA-29, accounted for most of the predicted effect.

Then they tested it. Ten sedentary adults averaging 69 years, eight of them women, completed a 12-week program that built from 70 to 150 minutes of moderate aerobic activity per week. Blood was drawn before and after. Vesicles from each draw were applied to cartilage cells from a 65-year-old donor grown on a gel as stiff as aged cartilage, a condition that normally drives the cells into an aged, flattened, matrix-degrading state.

Vesicles collected after training reversed much of that. The cells rounded up, made more type II collagen and aggrecan, and produced less of the enzymes MMP13 and ADAMTS4 that chew through cartilage. Levels of DNMT1, an enzyme that silences genes by methylating DNA, fell. Methylation of the Klotho promoter dropped and alpha-Klotho protein rose. Vesicles collected before training did little.

In old mice, each animal received pre-training vesicles in the left knee and post-training vesicles in the right, twice weekly for four weeks. Knees given post-training vesicles showed lower cartilage damage scores, more collagen and less degradative enzyme.

Finally, the researchers loaded vesicles with synthetic microRNA-29. These reproduced the anabolic shift in cells, and silencing Klotho partly blocked it. The authors conclude that a microRNA-29 to Klotho axis carries part of the benefit of exercise to the joint.

The idea is attractive, and the paper is open about some gaps. It never shows that circulating vesicles penetrate human cartilage in meaningful numbers. The trial that supplied the blood was terminated when funding ended, so no pain, function or imaging data exist for these participants. There was no non-exercising comparison group, so seasonal or other time-related changes in blood cannot be excluded.

Other gaps go unremarked. Of the two microRNA-29 members measured in the participants, only one reached conventional statistical significance, and the rise was concentrated in a few individuals. The mouse experiment had no saline-injected knee, so it shows a difference between two vesicle preparations but not a benefit over doing nothing. And microRNA-29 is not a simple youth signal: other work links elevated microRNA-29 to aging phenotypes in mice.

The result is a well-built hypothesis with early supporting data. It does not justify exosome injections or microRNA therapies for arthritic knees.

Actionable Insights

The paper is a reason to keep doing aerobic exercise.

  • The program used was modest: five sessions a week of self-rated moderate effort, building from 10 to 30 minutes each, mostly at home, for 12 weeks. Total weekly time was 70 to 150 minutes.
  • Body weight did not change (83.2 kg before, 83.4 kg after), so whatever shifted in the blood was not a weight-loss effect.
  • No joint outcome was measured in people. The only tissue-level result is in mice, where knees given post-exercise vesicles scored roughly one-third lower on a 0 to 24 cartilage damage scale than the opposite knee given pre-exercise vesicles. That is a visual estimate from the published plot. The standardized effect is about 0.9, conventionally “large”, but it comes from nine animals and is likely inflated.
  • Response varied. The microRNA-29 increase was driven by a few of the ten participants. Not everyone may get this particular signal from this dose of exercise.
  • Nothing here supports commercial exosome products, Klotho boosters or microRNA supplements. The engineered vesicles were tested only on cells in a dish.
  • Resistance training was not studied. Its absence here says nothing about its value.

Context and Source

  • Paywalled Paper: Exercise enhances aged chondrocyte health through microRNA-29-enriched extracellular vesicles
  • Access: Paywalled. The article is published under exclusive licence to Springer Nature with no open access statement.
  • Institutions: Schoen Adams Research Institute at Spaulding, Harvard Medical School and Spaulding Rehabilitation Hospital (lead), with Columbia University Irving Medical Center, University of Pittsburgh and University of Kansas Medical Center
  • Country: USA
  • Journal: Nature Aging, published online 29 September 2026
  • Impact evaluation: The impact score of this journal is 25.0 (2025 Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

A Stanford-led team reconstructed the final 18 months of a 76-year-old cyclist with known structural heart disease who died of ventricular fibrillation three minutes after a hard Peloton session. His Apple Watch and Oura Ring recorded a coordinated shift in autumn 2024, four to six months before death: heart rate variability roughly halved, resting heart rate rose about 5 beats per minute, deep sleep fell by more than half, and estimated 6-minute walk distance dropped 50 meters. An echocardiogram in the same window showed severe mitral regurgitation and a severely dilated left ventricle. He then sharply increased his training frequency. The authors state plainly that one retrospective case cannot show that wearables predict sudden cardiac death.

On the evening of March 21, 2025, a 76-year-old man finished his 530th recorded Peloton workout. Three minutes later his Apple Watch registered a fall. His wife, a physician, started CPR and used the watch to call for help. Paramedics found ventricular fibrillation, and 39 minutes of resuscitation failed.

What makes the case unusual is the record he left behind. He had worn an Apple Watch for about five years and an Oura Ring for two, and had seven years of cycling logs and cardiac records. Researchers at Stanford, with colleagues in Bergen and Irvine, went back through all of it.

His heart was known to be damaged. In 2018, scans showed a scar from an old heart attack, a coronary calcium score of 1,350 and leaking mitral and aortic valves. By 2022 the mitral leak had worsened.

The wearable data show two clusters of change. The first, in spring 2024, followed hernia surgery and six weeks of enforced rest, and mostly involved walking and activity measures. The second, between late September and early December 2024, involved several body systems at once. His resting heart rate rose from 44 to 49 beats per minute. Two different devices recorded his heart rate variability falling by half or more. Deep sleep dropped from 39 to 18 minutes a night. His estimated walking capacity fell by about a tenth. None of these returned to their earlier levels.

During the same weeks he saw his primary care doctor for fatigue. A new murmur led to an echocardiogram on November 6, which showed a severely enlarged left ventricle and a severely leaking mitral valve. A cardiology appointment was eventually booked for a date that turned out to be 11 days after he died.

In the meantime he trained more, not less. In the first 79 days of 2025 he completed 69 indoor rides, more than in all of 2024, including a 24-day streak. His heart rate in the final session approached 150 beats per minute, above the simple age-based estimate of his maximum.

The authors argue that the signal worth watching is a sustained, multi-metric departure from a person’s own baseline, not any single abnormal reading. That is a reasonable hypothesis. It is not yet a tested one. The analysis was done after the outcome was known, there is no comparison with people whose wearables showed similar shifts and who did not die, and the autumn timing overlaps with seasonal change and a medication change.

There is also a less comfortable reading. The standard tools did work. A symptom, a stethoscope and an ultrasound identified severe valve disease four and a half months before death. What failed was the follow-through: the referral was slow and nobody told him to ease off. The wearable trace is a striking illustration, but the delay between the echocardiogram and the cardiology visit is the more direct lesson.

Actionable Insights

This paper tests no treatment, so there is no benefit to quantify. What it offers is a pattern to watch for, with the following magnitudes in one man.

Changes after the autumn 2024 shift, comparing 30 days before and after:

  • Heart rate variability: down 49 percent (Apple Watch) and 65 percent (Oura)
  • Resting heart rate: up 4.6 beats per minute, about 10 percent
  • Deep sleep: down 21 minutes a night, about 54 percent
  • Estimated 6-minute walk distance: down 50 meters, about 11 percent

Practical points:

  • Track your own baseline. A sustained shift across several metrics lasting weeks matters more than a bad night. [Confidence: Low to Medium, based on one case]
  • If you have known heart disease, unexplained fatigue plus this kind of shift is a reason to ask for re-evaluation, not a reason to train through it. [Confidence: Medium]
  • If imaging shows severe valve disease or a dilated ventricle, get specific exercise limits from a cardiologist before the next hard session. Do not wait months for the appointment. [Confidence: High, consistent with standard practice]
  • Wearables cannot rule out danger. Normal numbers do not mean a safe heart. [Confidence: High]

Context and Source

  • Open Access Paper: Longitudinal Changes in Wearable-Captured Physiology Before Sudden Cardiac Death
  • Institutions: Stanford University (lead and corresponding), University of Bergen, University of California Irvine
  • Country: USA, with Norway
  • Journal: JACC: Case Reports (Elsevier, for the American College of Cardiology Foundation)
  • Impact evaluation: The journal’s 2025 two-year impact factor is listed as 0.68. The impact score of this journal is 0.68, evaluated against a typical high-end range of 0 to 60+ for top general medical and science journals, therefore this is a Low impact journal.

RapAdmin

Researchers in Glasgow and Edinburgh built the first sequencing-based epigenetic clock for the zebra finch and applied it to nestlings fed corticosterone, the bird equivalent of cortisol (the stress hormone), for 17 days. Treated chicks read about 11 days older than controls at a true age of 29 days. One gene, ZBTB16, lost roughly half its methylation and matched levels seen in birds older than two years. The authors argue that early stress shifts the blood methylome toward an aged state through metabolic pathways tied to longevity.

Hard early lives tend to be shorter lives. That pattern shows up in humans, baboons, deer and birds, but nobody has pinned down the mechanism. Human studies cannot separate childhood stress from poverty, diet and genetics. Experiments on newborn rodents are awkward because the pups cannot be handled without disturbing the mother.

Zebra finches get around this. Chicks develop in the nest after hatching, so researchers can dose them directly. Earlier work from the same Glasgow group reported that chicks given extra corticosterone became more stress-reactive adults and died about 30 percent sooner. The new preprint asks what that hormone does to the DNA within days of exposure.

The team first needed a way to measure biological age. They sequenced DNA methylation, the chemical tags that change predictably with age, in red blood cells from birds aged one day to more than nine years. From over 2,000 candidate models they chose a clock that predicted age to within 80 days on average in birds it had not seen, and to within 8 days in young chicks.

Then came the experiment. Forty-eight chicks received corticosterone in peanut oil twice daily from day 12 to day 28. Forty-eight controls got oil alone. At about 29 days old, the treated birds read 11 days older on the clock.

The more striking result involved ZBTB16, a gene switched on by stress hormones in mammals, birds and fish. Its methylation fell by 30 percentage points in treated chicks, landing at levels normally seen only in birds past two years old. Unlike another stress gene, FKBP5, it showed no sign of recovering over the four days after dosing stopped. The authors suggest ZBTB16 acts as a molecular memory of stress that keeps metabolism in survival mode and, over years, wears the body down.

Three cautions apply. First, nobody followed these particular birds to see how long they lived, so the link between the methylation shift and early death is borrowed from older studies. Second, the claim that stressed chicks resemble six-month-old birds comes from 111 DNA sites chosen partly because they sat in regions that already responded to the hormone, which tilts the comparison. Across all 5,129 age-related sites, treated chicks moved in the aging direction only about half the time. Third, the genes involved are classic direct targets of stress hormones, and blood was drawn one to four days after the last dose. What looks like accelerated aging may partly be the ordinary short-term footprint of a steroid.

Actionable Insights

This paper tests a harm, not a treatment. The useful lessons are indirect.

How big was the effect? Treated chicks read 11 days older at 29 days of age, about 38 percent of their actual age. In standardized terms that is a Cohen’s d of roughly 0.85, conventionally a large effect. In plain language, about 8 in 10 treated chicks read older than the average control, though the two groups still overlapped considerably. Treatment and the other measured factors explained only about 15 percent of the variation between birds. Which nest a chick came from mattered more.

Practical points:

  • The findings support taking chronic stress in children seriously, but they do not quantify human risk.

Context and Source

Leitura Relacionada:

RapAdmin

This 2017 review from UC Berkeley argues that the lighter, shorter, more broken sleep of later life is not a sign that older people need less sleep. Deep-sleep brain waves weaken by 75 to 80 percent over the frontal lobes, the decline starts in the 30s, and it is far steeper in men. The authors link these losses to shrinkage in specific brain regions and to a dulled response to the brain’s own sleep-pressure signal, and they tie the weakened sleep to poorer memory. The evidence is mostly correlational, and no reliable way to restore deep sleep has been shown.

It is one of the most familiar assumptions about ageing: grandparents rise at dawn and doze after lunch because older people need less sleep. A review from the University of California, Berkeley, argues that this has the story backwards.

Bryce Mander, Joseph Winer and Matthew Walker draw together roughly 160 studies. The decline they describe begins earlier than most people expect. Deep sleep starts to erode in the 30s. By the 70s, the slow electrical waves that define deep sleep are 75 to 80 percent weaker over the front of the brain than in young adults. Sleep spindles, the brief bursts of activity linked to learning, fall by up to half late in the night. Sleep becomes shorter, lighter and more fragmented.

The sex difference is large. In a cohort of more than 2,500 adults, men over 70 had half the deep sleep of men under 55, while women showed no significant decline. Yet women report more sleep complaints, a mismatch nobody has explained.

The review traces these changes to wear in particular brain structures. Sleep-promoting neurons in the hypothalamus dwindle. The orexin cells that keep sleep and wake states stable thin out. The body clock’s signal flattens. And the medial prefrontal cortex, where slow waves are generated, loses grey matter. The more that region has shrunk, the weaker a person’s slow waves.

The most interesting argument concerns adenosine, the chemical that builds up during waking hours and creates the pressure to sleep. If older people needed less sleep, they should accumulate less of it. Rodent studies show the opposite: older brains carry more. What declines is the number of receptors that detect it. On this reading, the signal is still being sent but is poorly received.

The consequences show up in memory. Older adults with the weakest slow waves forget more overnight, and those with the fewest spindles learn less the next day. Statistically, the sleep deficit accounts for these memory gaps better than age does. In one experiment, disturbing deep sleep with sounds impaired older adults’ learning the next day even though total sleep time was unchanged.

Fixing the problem is harder. Conventional sleeping pills can increase time in deep sleep, but they generally fail to deliver the memory benefit and sometimes impair recall. Gentle electrical or sound stimulation timed to slow waves has improved memory in some small studies and failed in others.

The case has real weaknesses. This is a narrative review, not a systematic one, and several of its central claims rest on small studies from the authors’ own laboratory. Most of the evidence compares young and old people at a single point in time, which cannot show that poor sleep causes memory decline. The authors themselves say there is no consensus. The paper is also nine years old, and the science of sleep drugs and dementia has moved since.

Still, the central message is that feeling less sleepy with age is not good evidence of needing less sleep.

Insights

What this review offers is a better way to think about sleep in midlife and beyond.

  1. Do not treat low sleepiness as proof of enough sleep. Older adults feel less sleepy even when memory measures suggest a shortfall.
  2. Hours slept and tracker stage totals miss the main change. Deep-sleep wave strength falls 75 to 80 percent over the frontal lobes even when stage durations look similar.
  3. Men should start early. Slow wave activity is already about 50 percent lower in men in their 30s than in their 20s (25 percent in women). By the 70s, men’s deep sleep falls from roughly 13 percent of the night to about 5 percent, or approximately 65 minutes down to 25 in an eight-hour night.
  4. Address fixable disruptors: sleep apnea, pain, nighttime urination, alcohol, and medications such as some blood pressure drugs that disturb deep sleep. Ask a clinician before changing any prescription.
  5. Be wary of sedative sleeping pills for cognitive purposes. They add deep-sleep time without the memory benefit and can impair recall.
  6. Treat stimulation devices as experimental. One young-adult study nearly doubled overnight retention, but three trials in the review found nothing.

Context and Source

  • Open Access Paper: Sleep and Human Aging
  • Institution: Sleep and Neuroimaging Laboratory, Department of Psychology, and Helen Wills Neuroscience Institute, University of California, Berkeley
  • Country: USA
  • Journal: Neuron, 2017
    Impact evaluation: The impact score of this journal is 16.9, evaluated against a typical high-end range of 0 to 30 for specialist neuroscience journals (0 to 60+ for top general science), therefore this is an Elite impact journal within its field.

Leitura Relacionada:

RapAdmin

Researchers at the Buck Institute built gene-expression aging clocks for 48 human tissues using GTEx, a post-mortem database where many donors gave both blood and tissue samples. They then trained blood-only models to estimate each organ’s “age,” along with organ-level senescence and hallmark-of-aging scores. They went on to build cheaper stand-ins from blood DNA methylation and from facial photographs. Methylation-derived organ ages predicted ten-year mortality in the Framingham Heart Study (AUC about 0.74; 0.76 for cardiovascular death). Face-derived organ ages predicted twenty-year survival in a celebrity photo database (AUC 0.74). Blood tracked organ age moderately well for some tissues and poorly for others.

Every organ ages on its own schedule. Your arteries may be a decade ahead of your liver, and your brain may lag behind both. Measuring this directly means taking tissue samples, which nobody does to healthy people out of curiosity. A team at the Buck Institute for Research on Aging in California proposes a workaround that runs through the bloodstream and, more ambitiously, through a photograph of your face.

The group, led by David Furman, started with GTEx. This reference library records gene activity in dozens of tissues from roughly a thousand deceased donors. Because many donors gave both blood and tissue, the researchers could ask a direct question. Does gene activity in someone’s blood carry a readable echo of what is happening in their thyroid, colon or heart? They built aging clocks for 48 tissues, then trained blood-only versions to predict each organ clock.

The answer was a qualified yes. A handful of tissues worked well: thyroid, breast, sigmoid colon, tibial artery, skin and oesophagus. For these, blood-based estimates tracked age reasonably closely in people the models had not seen. Blood-based estimates for 34 of 45 workable tissues cleared a modest bar. For others, accuracy collapsed toward nothing on new data. Typical errors were 8 to 13 years.

The team then scored each organ for signatures of cellular senescence and for the broader hallmarks of aging. Senescence is the state in which damaged cells stop dividing and secrete inflammatory signals. The standard senescence gene sets showed no relationship with age at all. The scores only began to rise with age after the researchers split each gene set by whether its genes went up or down with age.

Next came the cheap proxies. The team used 605 participants from a trial run by Edifice Health, a company that employs two of the authors. With them, they trained models that estimate blood-derived organ ages from facial photos taken on an iPad. A parallel model did the same from blood DNA methylation in the Health and Retirement Study. Neither stand-in is precise, but both carried some signal into survival. In the Framingham Heart Study, methylation-based organ ages split people into higher and lower ten-year death risk. In a set of celebrity photos from IMDb and Wikipedia, face-based organ ages predicted twenty-year survival with similar accuracy.

Within one person, organ ages mostly moved together, with an average correlation of about 0.44 between organs, yet some pairs ran in opposite directions. A mediation analysis suggested that genes in one tissue might influence aging genes in another through the blood. Most of these links stayed within a single organ. A drug-matching screen flagged compounds whose known gene targets overlap the clock genes, among them N-acetylglucosamine.

The pitch is appealing: a selfie or a cheap blood test that flags which organ is running fast, followed by a targeted fix. What the data show today is more modest. This is an unreviewed preprint built on post-mortem tissue. Prediction errors run to decades for the facial models, and it has not been tested whether organ age adds anything beyond a person’s actual age. It is an interesting research direction, time will tell if it becomes accurate enough to be valuable.

Actionable Insights

The useful lessons are about how to read the consumer products likely to follow.

First, organ-age readouts from blood or photos are not ready to guide personal decisions. In the best tissues, blood explained about 36 percent of the variation in organ age (correlation 0.6). In a typical usable tissue it explained about 9 percent (correlation 0.3). Facial estimates often explained 4 percent or less (correlation 0.2), with errors that could exceed 30 years. A single reading is mostly noise.

Second, several standard lab markers tracked with older organ ages across many systems, and you can already measure them. Rising CRP, IL-6, soluble TNF receptor 1, IL-1RA and cystatin C went with older organ ages. Higher albumin and lymphocyte counts went with younger ones. These are established risk markers in their own right. The paper reports no effect sizes for them.

Third, the mortality split sounds dramatic. In Framingham’s test set, about 7 in 10 of the high-risk half were alive at ten years, against roughly 9 in 10 of the low-risk half. That is close to three times the death risk. Chronological age probably drives much of that gap.

Fourth, ignore the compound list. N-acetylglucosamine and the others were flagged by overlap between gene lists, not by any test of whether they change organ aging.

Context and Source

Leitura Relacionada: